Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is an exploratory, proof of concept study to evaluate the safety and efficacy of
RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in
patients with ptosis.